Why TFA Salts Can Skew Cell Proliferation Assays

Introduction

This article is for research use only. If a synthetic peptide appears to slow cell growth in a proliferation assay, the peptide may not be the cause. Most peptides purified by HPLC arrive as trifluoroacetate (TFA) salts, and the TFA counterion has its own published effects on cultured cells. In short, what looks like a property of the peptide can be a property of its salt form.

If you read published cell-culture data, or plan your own, this matters. The artifact is easy to miss and just as easy to avoid. Below we cover where TFA comes from, what the early osteoblast and chondrocyte data showed, how much TFA a peptide salt can carry, why the bias can run in either direction, and what controls and counterion exchange can do about it.

Where TFA comes from in synthetic peptides

Short answer: TFA is part of how most synthetic peptides are made and purified, so it is usually still there when the vial arrives.

Two steps put it there. Trifluoroacetic acid is used to cleave a finished peptide from its synthesis resin, and it is also a common ion-pairing agent in reversed-phase HPLC purification. After purification the peptide is typically isolated as a TFA salt, with trifluoroacetate paired to the positively charged groups: lysine, arginine and histidine side chains and the free N-terminus.

That pairing sticks. Freeze-drying alone doesn't strip it all away, and a peptide described as "98% pure by HPLC" can still be a TFA salt, because HPLC purity describes the peptide-related species, not the counterion. Think of the peptide as the guest and TFA as the luggage that came with it.

What the osteoblast and chondrocyte data showed

Short answer: a 1999 study found that very low concentrations of TFA alone slowed growth in bone and cartilage cells.

The paper, titled "Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes", tested TFA directly. In cultures of fetal rat osteoblasts, TFA at 10^-8 to 10^-7 M lowered both cell number and thymidine incorporation, a standard readout of DNA synthesis, after 24 hours. Similar effects were reported in articular chondrocytes and in neonatal mouse calvariae (bone explants), so the finding did not hinge on one cell type or one species.

The authors drew a broader conclusion: the concern applies to purified peptides used above roughly 10^-9 M in any cell or tissue type. That's a low bar. Many in-vitro peptide experiments work at concentrations well above it, which means the counterion can be present at an effective level in routine assays.

One caveat: we worked from the abstract-level description of the study, so we don't quote its full methods. What matters is that TFA alone, with no peptide present, changed proliferation readouts in primary-type cells.

How much TFA is actually in a peptide salt

Short answer: a lot. By weight, TFA can be a quarter or more of what you weigh out.

A 2025 study on analysis and exchange of TFA as a counterion put numbers on it. Across seven synthetic peptides, the theoretical TFA share of the salt weight ranged from 21.9% to 35.2%. One purified peptide measured 0.333 ± 0.008 mg of TFA per mg of peptide salt by HPLC with evaporative light-scattering detection. The authors note TFA can reach up to 35% of total salt weight.

Two practical consequences:

• Weighed mass is not peptide mass. If a stock solution is made by weight, the real peptide concentration is lower than planned, and the TFA concentration is a fixed fraction of what you added. This is the same gap that separates net peptide content from HPLC purity.
• TFA scales with the peptide. Every time you raise the peptide concentration in a concentration-series experiment, you raise the TFA concentration in lockstep, so a concentration-dependent effect can come from either one.

Labs measure the counterion with methods such as 19F-NMR and HPLC-ELSD; our overview of how labs quantify residual TFA covers the approaches in more detail.

The bias can run either way

Short answer: residual TFA has been reported to both inhibit and increase proliferation, so you cannot assume which way it will push your data.

The 2025 counterion study summarizes prior work in which residual TFA both increased and inhibited cell proliferation and raised cell toxicity. A separate case study on counterions in biological activity notes that residual TFA or TFA-acetate levels in final samples can reach about 10^-7 M, which sits inside the range the osteoblast study flagged. That same case study also cites TFA as favoring the viability of several cell types unspecifically.

The field has not settled how strongly counterion identity changes activity. In the authors' own antibacterial data, two salt forms of one compound looked alike overall, while certain resistant isolates showed large differences between salt forms. They call the question controversial and say a clear link between counterion type and in-vitro activity still has to be established. For anyone designing an assay, the takeaway is to test it per compound and per cell system rather than assume either "TFA matters" or "TFA never matters."

The failure modes are easy to picture.

• A peptide with a modest real effect looks inactive because its TFA load pushes the readout the other way.
• A peptide with no real effect looks antiproliferative because its TFA load slows the cells.
• A negative-control peptide fails to behave like a control because it carries the same counterion burden as the test peptide, or a different one.

Designing the assay so the counterion is visible

Short answer: treat the counterion as a variable you can measure and control, not as background.

A few habits keep it from skewing results:

• Add a counterion-matched control. Include wells that receive sodium trifluoroacetate at the TFA concentration the test peptide delivers. If those wells move, the counterion is contributing.
• Compare salt forms side by side. Where material is available, run the TFA form and a chloride or acetate form of the same peptide in the same plate. Agreement between them is reassuring; disagreement tells you the salt matters.
• Calculate concentration from net peptide content. Use measured peptide content rather than gross weighed mass, so the peptide and TFA concentrations are both known.
• Quantify and report the counterion. A method such as HPLC-ELSD can measure common counterions in peptides together, which is why a published mixed-mode chromatography method stresses determining counterion identity and amount so cell assays are not biased by it. In 19F-NMR, TFA gives a signal near 75.4 ppm; FT-IR can confirm the C-F band near 1200 cm^-1 but the 2025 study judges it suitable for qualitative confirmation only.
• Write it in the methods. State the salt form and the measured TFA content so another lab can interpret the result. A supplier's certificate of analysis is the first place to look for what was reported.

Exchanging the counterion before the assay

Short answer: if TFA is a problem, it can be swapped for chloride or acetate, with some trade-offs.

The classic approach is repeated freeze-drying from dilute hydrochloric acid. The 2025 study tested it systematically: peptides at 1 mg/mL in dilute HCl were frozen at −80 °C and freeze-dried. With 10 mM HCl, TFA fell below the quantification limit of all three analytical techniques after a single round; weaker HCl solutions (5 mM and 2 mM) needed two and three rounds. Purity stayed above 96% across the tested concentrations and three rounds, and 10 mM was identified as the best choice. An earlier critical evaluation of exchange approaches adds that very low pH can degrade some peptides, so purity should be rechecked afterward.

Acetate is the other common destination. TFA can be swapped for acetate by reversed-phase HPLC or ion-exchange resin, with partial to near-complete exchange, and acetate is a weaker acid than TFA. Our article on TFA-to-acetate counterion exchange explains why quality-control teams care about this step. Whichever route is used, confirm the result by measurement. An exchange that was never verified is just a hope.

A 2025 permeation study in the same paper found that results depended on both the peptide sequence and the salt form, which is a reminder that exchange can change behavior as well as remove an artifact. That's a reason to report both forms, not a reason to skip exchange.

Conclusion

TFA isn't a rare contaminant. It's the default companion of an HPLC-purified synthetic peptide, and it can account for a large share of the weighed material. A 1999 study showed it can slow osteoblast and chondrocyte proliferation at 10^-8 to 10^-7 M by itself, and later literature describes effects in both directions. The sensible response is practical: measure the counterion, add a matched control, consider an exchange to chloride or acetate, and report the salt form with the data.

Frequently Asked Questions

Why is TFA present in research peptides at all?

TFA is used to cleave synthetic peptides from the resin and as an ion-pairing agent in reversed-phase HPLC purification, so the purified peptide is typically isolated as a TFA salt, with TFA paired to basic residues and the N-terminus.

Does TFA always slow proliferation in cell assays?

No. Published reports describe residual TFA both inhibiting and increasing proliferation, depending on the system, which is why the direction of the artifact cannot be assumed and a counterion-matched control is useful.

What is a counterion-matched control?

It is a control well that receives sodium trifluoroacetate, or a TFA-free salt form of the same peptide, at the concentration of TFA delivered by the test peptide, so any effect of the counterion itself can be separated from the effect of the peptide.

How is residual TFA measured?

Common methods include 19F-NMR and HPLC with evaporative light-scattering detection. FT-IR is generally used for qualitative confirmation because of its higher quantification limit.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.